A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation
Study sponsor: Verastem, Inc. · VSTM
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-11-15Actual
Enrollment · participants225Estimated
Source updated2025-01-29Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.